Elekta Ab Class B · OMXSTO:EKTA_B
Elekta Ab Class B — Investor Presentation (February 2013)
14 slides from Elekta Ab Class B's investor presentation, Feb 28, 2013
Slide 1: Tomas Puusepp and Dee Mathieson
Tomas Puusepp CEO and President, Elekta AB Dee Mathieson Senior Vice President, Oncology Business Line Management
Slide 2: Introducing Versa HD
Introducing Versa HD Versa HD is not available for sale or distribution in all markets. Please contact your Elekta representative for details.
Slide 3: Double the number of patients to be treated
Double the number of patients to be treated Aspiration 2 million • The pioneer of modern cancer patients care since 1972 • One of the fastest growing companies in the industry • IGRT 2005, PerfexionTM 2006, VMAT 2008, AgilityTM 2012, etc. • Last year close to 1,000,000 Today: close to patients benef
Slide 4: Increasing population with cancer
Increasing population with cancer 1. Number of new cancer cases 2. Increasing population living Millions with cancer 25 • Improved treatments - cancer Total becomes more of a chronic 20 disease 15 Men • Re-treatments 10 Women 5 0 2010 2015E 2020E 2025E 2030E • World population growth to 2030: +20% •
Slide 5: Well positioned for further growth
Well positioned for further growth 1. Enables higher dose per session – delivered more than three times faster than before. 2. Minimizes dose to healthy tissue. MLC leaf speeds more than twice as fast as other systems. 3. New generation of patient specific treatments Versa HD is a key in Elekta’s gr
Slide 6: Market dynamics
Market dynamics • Linac-based SRS/SRT systems is expected to be the fastest growing segment on the market • Over 85% of that market will require a highly versatile system capable of a wide spectrum of therapies IMV Report - February 2012
Slide 7: Versatility
Versatility + = Conventional Advanced Versa HD radiotherapy stereotactic precision One Solution. Unlimited Possibilities.
Slide 8: Innovation through collaboration
Innovation through collaboration Translating clinical research into patient benefits • Elekta Lung Research Group • Evaluating clinical outcomes in early stage inoperable non- small cell lung cancer • Accumulated data for over 800 patients • Identified medical and technical factors that affect tumor
Slide 9: Versa HD lung treatment
Versa HD lung treatment Treatment 4D Advanced Treatment Gating Planning Image Guidance Delivery Accurate dose Optimized Reduce High-resolution MLC calculation Dose Placement intra-fraction with motion High Dose Rates Protect Critical Structures MOSAIQ OIS Delivering ‘Evidence based Medicine’ Wolthau
Slide 10: Versa HD lung treatment
Versa HD lung treatment High Dose Rate mode • Improve treatment times with escalated SRS/SRT dose regimens Previous Lung Versa HD Generation PTV prescription 60 Gy 60 Gy Number of fractions 5 5 Dose per fraction 12 Gy 12 Gy 3 mins 2 mins Beam-on time per fraction 50 seconds 10 seconds 49% faster Dat
Slide 11: Enhanced patient and clinician experience
Enhanced patient and clinician experience Confident and relaxed treatment environment Fewer delays and reduced downtime • 30% less power consumption • Lower operating temperature • Reduced cost of operation
Slide 12: Well positioned for further growth
Well positioned for further growth 1. Enables higher dose per session – delivered more than three times faster than before. 2. Minimizes dose to healthy tissue. MLC leaf speeds more than twice as fast as other systems. 3. New generation of patient specific treatments Versa HD is a key in Elekta’s gr
Slide 13: Q&A
Q&A Versa HD is not available for sale or distribution in all markets. Please contact your Elekta representative for details.
Slide 14: www.VersaHD.com
| www.VersaHD.com